Erasca Q1 2024 Earnings Report

Erasca EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$0.21
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Erasca Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Erasca Announcement Details

• Quarter: Q1 2024
• Date: 5/8/2024
• Time: N/A
• Conference Call Date: Wednesday, May 8, 2024
• Conference Call Time: 4:00PM ET

Erasca (NASDAQ:ERAS) is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for patients with cancer. The company’s research efforts focus on creating small-molecule inhibitors that target key signaling pathways known to drive tumor growth and resistance. Erasca’s pipeline comprises multiple differentiated programs in development for indications including colorectal cancer, lung cancer, melanoma and other solid tumors. Through selective targeting of molecular drivers such as KRAS, PI3Kα and MEK1/2, Erasca aims to advance novel oncology treatments that offer improved efficacy and safety profiles compared to existing standards of care.

Among its lead assets, ERAS-007 is a potent and selective inhibitor of KRAS G12C, currently in early clinical evaluation for patients whose tumors harbor this mutation. ERAS-601 is a precision PI3Kα inhibitor designed to address tumors with relevant pathway activation, and ERAS-853 is a next-generation MEK1/2 inhibitor being studied across a range of solid-tumor indications. Erasca conducts its research and development activities through facilities in South San Francisco as well as in partner sites, leveraging state-of-the-art preclinical and translational platforms to accelerate candidate selection and clinical validation.

Founded in 2017 and headquartered in South San Francisco, Erasca has assembled a leadership team with deep expertise in oncology drug development. Chief Executive Officer Peter Nielsen brings more than two decades of experience leading clinical and translational efforts in both large biopharma and emerging biotech settings. The senior management team includes seasoned professionals in clinical operations, regulatory affairs and medicinal chemistry, all collaborating to navigate the complex pathways of oncology drug development from discovery through clinical proof of concept.

Erasca is committed to expanding its global footprint through strategic collaborations and by advancing its clinical programs into later-stage trials. The company actively engages with key opinion leaders, academic institutions and patient advocacy groups to ensure that its development strategy aligns with unmet medical needs. With a focus on disciplined execution and scientific innovation, Erasca seeks to deliver transformative therapies that improve outcomes for cancer patients worldwide.